GlassScriptPhysician profile
Jaime K Anderson
NPI 1477684900
$3,223.98
in general payments reported to CMS, 2019-2025
27 companies · $872 in 2025
The $872 reported for 2025 was more than what 96% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $353 · 2023: $621 · 2024: $1,183 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,675.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $871.47 | 2021-2025 | |
| Corium, LLC | $371.44 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $343.00 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $257.73 | 2023-2025 | |
| Cranial Technologies, INC | $205.54 | 2022-2025 | Doc Band |
| Glaxosmithkline, LLC. | $193.39 | 2022-2025 | Bexsero, Rotarix, Penmenvy |
| Takeda Pharmaceuticals U.S.A., INC. | $143.36 | 2021-2023 | Trintellix |
| Ars Pharmaceuticals Operations, INC. | $139.40 | 2025 | Neffy |
| Kaleo, INC. | $108.56 | 2021-2024 | Auvi-Q |
| Tris Pharma INC | $89.56 | 2021-2025 | Dyanavel Xr, Quillichew Er |
| Phadia US INC. | $52.94 | 2022-2024 | Immunocap |
| Vertical Pharmaceuticals, LLC | $48.26 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $47.57 | 2025 | Jornay Pm |
| Cepheid | $40.36 | 2023 | Genexpert |
| Pfizer INC. | $39.56 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $34.41 | 2023 | Ragwitek, Odactra, Grastek |
| Sanofi-Aventis U.S. LLC | $28.57 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $25.83 | 2024 | Xarelto |
| Qol Medical, LLC | $25.32 | 2022 | |
| Organon LLC | $23.80 | 2025 | |
| Ironwood Pharmaceuticals, INC | $22.97 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $22.11 | 2022 | |
| Verrica Pharmaceuticals INC. | $20.96 | 2024 | Ycanth |
| Supernus Pharmaceuticals, INC. | $20.81 | 2025 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $18.33 | 2024 | Zoryve |
| Seqirus USA INC | $15.76 | 2025 | Flucelvax |
| Aytu Biopharma, INC. | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.